Skip to main content

Table 2 Performance of plasma Aβ42/Aβ40 to predict PET positivity and concordance with PET

From: Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

  AUC (unadjusted) AUC (adjusted) Concordant/total casesa (concordance rate) Discordant casesa
Plasma+/PET− Plasma−/PET+
Total 0.814 0.920b 384/503 (76.3%) 60 (11.9%) 59 (11.7%)
OC 0.826 0.890c 114/148 (77.0%) 29 (19.6%) 5 (3.4%)
aMCI 0.815 0.872c 158/210 (75.2%) 23 (11.0%) 29 (13.8%)
ADD 0.812 0.877c 99/130 (72.7%) 6 (4.6%) 25 (19.2%)
YC NA NA 13/15 (86.7%) 2 (13.3%) NA
  1. PET positron emission tomography; ADD Alzheimer’s disease dementia; aMCI amnestic mild cognitive impairment; OC old controls; YC young controls; AUC area under the receiver operating characteristic curve
  2. aThis concordance classification was based on the plasma Aβ42/Aβ40 ratio of 0.2576 obtained from the total group
  3. bLogistic analysis after adjusting for age, APOE4 status, and diagnosis
  4. cLogistic analysis after adjusting for age and APOE4 status